Gomollón Fernando, Gisbert Javier P
Gastroenterology Unit, Clinical Universitary Hospital Lozano Blesa, CIBEREHD, Avenida San Juan Bosco 15, Zaragoza 50009, Spain.
World J Gastroenterol. 2009 Oct 7;15(37):4659-65. doi: 10.3748/wjg.15.4659.
Too often anemia is considered a rare or unimportant manifestation in inflammatory bowel disease (IBD). However, over the last 10 years a number of studies have been conducted and the most relevant conclusions obtained are: (1) anemia is quite common in IBD; (2) although in many cases anemia parallels the clinical activity of the disease, many patients in remission have anemia, and iron, vitamin B12 and/or folic acid deficiency; (3) anemia, and also iron deficiency without anemia, have important consequences in the clinical status and quality of life of the patient; (4) oral iron can lead to gastrointestinal intolerance and failure of treatment; (5) intravenous iron is an effective and safe way to treat iron deficiency; (6) erythropoietin is needed in a significant number of cases to achieve normal hemoglobin levels. Thus, the clinician caring for IBD patients should have a comprehensive knowledge of anemia, and apply recently published guidelines in clinical practice.
在炎症性肠病(IBD)中,贫血常常被视为一种罕见或不重要的表现。然而,在过去10年里进行了多项研究,得出的最相关结论如下:(1)贫血在IBD中相当常见;(2)尽管在许多情况下贫血与疾病的临床活动平行,但许多缓解期患者仍有贫血,且存在铁、维生素B12和/或叶酸缺乏;(3)贫血以及无贫血的缺铁对患者的临床状况和生活质量有重要影响;(4)口服铁剂可导致胃肠道不耐受和治疗失败;(5)静脉铁剂是治疗缺铁的有效且安全的方法;(6)在相当多的病例中需要使用促红细胞生成素来使血红蛋白水平达到正常。因此,照料IBD患者的临床医生应全面了解贫血,并在临床实践中应用最近发布的指南。